Value
7.7/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 5.8 |
| Analyst target | 9.0 |
- ▸Attractively valued
RGNX · Why this verdict
Why REGENXBIO (RGNX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
REGENXBIO shows extreme technical overextension and sub-floor quality metrics alongside a persistent earnings-miss streak, but bullish analyst sentiment and elevated options activity suggest the market is still pricing in a meaningful clinical or regulatory catalyst.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Options markets show an elevated put/call ratio of 2.84 and high implied volatility of 123%, indicating the market is pricing in a significant probability of a large price move — likely tied to an upcoming clinical or regulatory event. Risk breakdown | Implied volatility should decline toward historical norms (below 100%) once the anticipated catalyst passes without a major surprise. | — |
| CounterA high put/call ratio could also reflect hedging by long holders rather than outright bearish bets, which would not necessarily predict a price decline. | ||
RGNX's RSI has reached an extreme 97 with a flattening-to-negative 200-day moving average slope, which the engine explicitly flags as late-cycle distribution risk — suggesting the current rally is stretched and vulnerable to a sharp reversal. Momentum breakdown | RSI should cool meaningfully from 97 toward more sustainable levels (below 60) without a disorderly price collapse. | — |
| CounterIn a binary biotech name, an extreme RSI can also reflect genuine re-rating around a specific catalyst, in which case the overextension doesn't necessarily predict a reversal. | ||
The company's quality score falls below the engine floor, driven by cash burn (FCF at -158% of revenue) and a weak Piotroski F-Score of 2 out of 9, meaning the balance sheet has little cushion if commercialization is delayed. Quality breakdown | Cash burn should moderate and the Piotroski score should improve toward the mid-single digits as the business matures. | — |
| CounterHeavy cash burn is typical and expected for a clinical/commercial-stage gene-therapy company still scaling its pipeline, so this metric may be a poor predictor of ultimate success. | ||
The company has missed consensus estimates in 3 of its last 4 quarters with an average surprise of -25%, suggesting a pattern of overly optimistic estimates that the business has repeatedly failed to meet. Avg surprise pct | The miss streak should break at the next report, or at minimum the average surprise should improve toward 0%. | — |
| CounterFor a clinical-stage biotech, EPS misses are often driven by R&D spending timing rather than commercial execution, making this a weaker signal of business health than it would be for a mature company. | ||
Despite the quality concerns, analysts see substantial upside (83%) and recent news sentiment is positive, indicating the sell-side still believes in a path to a much higher valuation. Sentiment breakdown | Analyst price targets should hold or increase over the next two quarters if the bullish thesis is intact. | — |
| CounterWith only light analyst coverage backing this figure, a single analyst's outsized target could be skewing the average upside estimate well above what a broader consensus would support. | ||
Options markets show an elevated put/call ratio of 2.84 and high implied volatility of 123%, indicating the market is pricing in a significant probability of a large price move — likely tied to an upcoming clinical or regulatory event.
—Risk breakdown
- Expectation
- Implied volatility should decline toward historical norms (below 100%) once the anticipated catalyst passes without a major surprise.
CounterA high put/call ratio could also reflect hedging by long holders rather than outright bearish bets, which would not necessarily predict a price decline.
RGNX's RSI has reached an extreme 97 with a flattening-to-negative 200-day moving average slope, which the engine explicitly flags as late-cycle distribution risk — suggesting the current rally is stretched and vulnerable to a sharp reversal.
—Momentum breakdown
- Expectation
- RSI should cool meaningfully from 97 toward more sustainable levels (below 60) without a disorderly price collapse.
CounterIn a binary biotech name, an extreme RSI can also reflect genuine re-rating around a specific catalyst, in which case the overextension doesn't necessarily predict a reversal.
The company's quality score falls below the engine floor, driven by cash burn (FCF at -158% of revenue) and a weak Piotroski F-Score of 2 out of 9, meaning the balance sheet has little cushion if commercialization is delayed.
—Quality breakdown
- Expectation
- Cash burn should moderate and the Piotroski score should improve toward the mid-single digits as the business matures.
CounterHeavy cash burn is typical and expected for a clinical/commercial-stage gene-therapy company still scaling its pipeline, so this metric may be a poor predictor of ultimate success.
The company has missed consensus estimates in 3 of its last 4 quarters with an average surprise of -25%, suggesting a pattern of overly optimistic estimates that the business has repeatedly failed to meet.
—Avg surprise pct
- Expectation
- The miss streak should break at the next report, or at minimum the average surprise should improve toward 0%.
CounterFor a clinical-stage biotech, EPS misses are often driven by R&D spending timing rather than commercial execution, making this a weaker signal of business health than it would be for a mature company.
Despite the quality concerns, analysts see substantial upside (83%) and recent news sentiment is positive, indicating the sell-side still believes in a path to a much higher valuation.
—Sentiment breakdown
- Expectation
- Analyst price targets should hold or increase over the next two quarters if the bullish thesis is intact.
CounterWith only light analyst coverage backing this figure, a single analyst's outsized target could be skewing the average upside estimate well above what a broader consensus would support.
Per-dimension breakdown
Quality
2.3/10data confidence 86%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.9 |
| FCF quality | 0.0 |
| Moat | 2.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -158% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 4.2 |
| Volume | 7.7 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+1.6%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 4.5 |
| Analyst rating | 7.0 |
| Price target | 10.0 |
- ▸Analyst upside: 146%
Insider
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 6.3 |
| notable moves | 7.0 |
- ▸Notable insider selling — $886,937 (0.153% of mkt cap)
Peer rank
1.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.4 |
| quality rank | 0.0 |
| growth rank | 0.2 |
Technical
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.4 |
| support resistance | 7.4 |
| 52w position | 2.2 |
| gap | 7.5 |
- ▸Extreme gap down (-19.7%) - potential reversal
Risk (lower is worse)
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.3 |
| days to cover | 6.1 |
| volatility | 0.0 |
| put call | 0.0 |
| beta | 7.6 |
| debt equity | 0.0 |
- ▸High short interest justified: 22%
- ▸Elevated put/call: 4.33
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.5/10data confidence 50%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| news activity | 8.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- ASYMMETRY:7.6>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.5<4.5
Warning (1)
- INSIDER:0.15%=MODERATE
Reward-to-Risk
7.61
Upside
+114.1%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.6B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.5<4.5 outcome against Value at 7.7 and asymmetric R:R of 7.61.
The strongest dimensions are Value at 7.7, Sentiment at 7.1, and Catalyst at 6.5; the weakest are Peer rank at 1.7, Quality at 2.3, and Risk (lower is worse) at 2.5. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 7.61 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Technical Overextension
Trip ifRSI falls below 30 within 2 months, a sharp reversal from the current 97 reading.
- P2Weak Quality Cash Burn
Trip ifCash burn exceeds -200% of revenue (FCF/revenue) in the next reported quarter.
- P3Elevated Options Hedging
Trip ifImplied volatility stays above 150% for 2 consecutive months.
- P4Persistent Earnings Misses
Trip ifThe company misses consensus EPS by more than 20% for a 4th consecutive quarter.
- P5Bullish Analyst Sentiment
Trip ifThe average analyst price target is cut by more than 30% from current levels.